Does Oral Implant Design Affect Marginal Bone Loss? Results of a Parallel-Group Randomized Controlled Equivalence Trial

Author:

Spies Benedikt C.12ORCID,Bateli Maria13,Ben Rahal Ghada1,Christmann Marin1,Vach Kirstin4,Kohal Ralf-Joachim1

Affiliation:

1. Department of Prosthetic Dentistry, Center for Dental Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

2. Department of Prosthodontics, Geriatric Dentistry and Craniomandibular Disorders, Charité Center for Dental and Craniofacial Sciences (CC3), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany

3. Private Practice, Freiburg, Germany

4. University Medical Center Freiburg, Center for Medical Biometry and Medical Informatics, Institute for Medical Biometry and Statistics, Freiburg, Germany

Abstract

Objective. To test whether or not the modified design of the test implant (intended to increase primary stability) has an equivalent effect on MBL compared to the control. Methods. Forty patients were randomly assigned to receive test or control implants to be installed in identically dimensioned bony beds. Implants were radiographically monitored at installation, at prosthetic delivery, and after one year. Treatments were considered equivalent if the 90% confidence interval (CI) for the mean difference (MD) in MBL was in between −0.25 and 0.25 mm. Additionally, several soft tissue parameters and patient-reported outcome measures (PROMs) were evaluated. Linear mixed models were fitted for each patient to assess time effects on response variables. Results. Thirty-three patients (21 males, 12 females; 58.2±15.2 years old) with 81 implants (47 test, 34 control) were available for analysis after a mean observation period of 13.9±4.5 months (3 dropouts, 3 missed appointments, and 1 missing file). The adjusted MD in MBL after one year was −0.13 mm (90% CI: −0.46–0.19; test group: −0.49; control group: −0.36; p=0.507). Conclusion. Both implant systems can be considered successful after one year of observation. Concerning MBL in the presented setup, equivalence of the treatments cannot be concluded. Registration. This trial is registered with the German Clinical Trials Register (ID: DRKS00007877).

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3